Skip to main content

Table 2 Correlation between CHD5 expression and clinicopathological parameters in breast cancer

From: Chromodomain helicase DNA binding protein 5 plays a tumor suppressor role in human breast cancer

Parameters CHD5 expression (n) Total cases P-values
  - +   
Age (years)    289 0.590
   ≤ 50 67 62 129  
   > 50 78 82 160  
Tumor size    288* 0.476
   ≤ 2 cm 29 34 63  
   > 2 cm 115 110 225  
Histological grade    275* 0.010
   I 4 14 18  
   II 100 103 203  
   III 34 20 54  
pTNM stage    284* 0.105
   I/II 99 111 210  
   III/IV 43 31 74  
LN metastasis    289 0.215
   - 57 67 124  
   + 88 77 165  
Estrogen receptor    289 0.009
   - 66 44 110  
   + 79 100 179  
Progesterone receptor    289 0.001
   - 84 54 138  
   + 61 90 151  
HER2 status    289 < 0.001
   - 74 111 185  
   + 71 33 104  
Molecular subtype    289 < 0.001
   luminal A 54 95 149  
   luminal B 35 12 47  
   HER2 37 20 57  
   Triple negative 19 17 36  
Family history    264* 0.420
   No 105 98 203  
   Yes 28 33 61  
Distant metastasis    289 < 0.001
   No 115 137 252  
   Yes 30 7 37  
Death    289 0.001
   No 125 140 265  
   Yes 20 4 24  
  1. Notes: LN, lymph node; pTNM, pathological tumor node metastasis; *, analysis was limited to patients whose relevant information was available. Molecular subtypes were defined as below: luminal A, ER+ and/or PR+/HER2-; luminal B, ER+ and/or PR+/HER2+; HER2+, ER-/PR-/HER2+; and triple negative, ER-/PR-/HER2-. CHD5 expression is categorized into two groups: lack of expression "-" and expression at various levels "+". P-values were determined by the Chi-square (χ2) test.